Combination pharmacotherapy for the treatment of the overactive bladder syndrome: a new solution for an old problem?
Author:
Publisher
Springer Science and Business Media LLC
Subject
Urology,Obstetrics and Gynecology
Link
http://link.springer.com/content/pdf/10.1007/s00192-019-04121-6.pdf
Reference12 articles.
1. Monteiro S, Riccetto C, Araujo A, Galo L, Brito N, Botelho S. Efficacy of pelvic floor muscle training in women with overactive bladder syndrome: a systematic review. Int Urogynecol J. 2018;29(11):1565–73. https://doi.org/10.1007/s00192-018-3602-x.
2. Goldman HB, Oelke M, Kaplan SA, Kitta T, Russell D, Carlsson M, et al. Do patient characteristics predict which patients with overactive bladder benefit from a higher fesoterodine dose? Int Urogynecol J. 2019;30(2):239–44. https://doi.org/10.1007/s00192-018-3640-4.
3. Wang CC, Jiang YH, Kuo HC. Efficacy and adherence of flexibly adding on a second antimuscarinic agent for patients with refractory overactive bladder. Low Urin Tract Symptoms. 2017;9(1):27–32. https://doi.org/10.1111/luts.12103.
4. Hsu FC, Weeks CE, Selph SS, Blazina I, Holmes RS, McDonagh MS. Updating the evidence on drugs to treat overactive bladder: a systematic review. Int Urogynecol J. 2019. https://doi.org/10.1007/s00192-019-04022-8.
5. Kelleher C, Hakimi Z, Zur R, Siddiqui E, Maman K, Aballea S, et al. Efficacy and tolerability of mirabegron compared with antimuscarinic monotherapy or combination therapies for overactive bladder: a systematic review and network meta-analysis. Eur Urol. 2018;74(3):324–33. https://doi.org/10.1016/j.eururo.2018.03.020.
Cited by 3 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Drug–Drug Interactions between Tamsulosin and Mirabegron in Healthy Individuals Do Not Affect Pharmacokinetics and Hemodynamic Parameters Significantly;Pharmaceuticals;2023-10-13
2. Adverse Events for Overactive Bladder Medications From a Public Federal Database;Female Pelvic Medicine & Reconstructive Surgery;2022-05-17
3. Systematic review and meta-analysis of the efficacy and safety of vibegron vs antimuscarinic monotherapy for overactive bladder;Medicine;2021-02-05
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3